http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NL-2020422-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ddcf2c315c108125b002b152dccca9cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9783a23cbf7ac30ae425a46e27109ce8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70532 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2018-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae421f68519d7e43d5922a52be6d0d72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d384f0d88b337e9228250199ebd77f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f996b53cdf796d98d4e341426761985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6e1267b854c7449a893a852deaaec6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59849ba663bdeebabe3ba8839698abff |
| publicationDate | 2019-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NL-2020422-B1 |
| titleOfInvention | Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy. |
| abstract | The present invention relates to the field of biomarker development for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds. Provided are assays for quantifying PD-1 expression (i.e. immunostaining intensity) in cells present in a tumor sample (i.e. intratumoral cells), which are advantageously used to identify a unique sub-population of intratumoral cells referred to herein as PD- 1T cells, which serves as a biomarker for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab). The present invention also provides methods of selecting a human subject diagnosed with cancer (e.g. non-small cell lung cancer (NSCLC)) suitable for immune checkpoint therapy with agents such as PD-1 inhibitors (e.g. nivolumab) and/or PD-L1 inhibitors (e.g. atezolizumab) alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab), methods for predicting responsiveness to immune checkpoint therapy with agents such as PD-1 inhibitors and/or PD-L1 inhibitors, and method of treatment of a human subject diagnosed with cancer using PD-1 inhibitors and/or PD-L1 inhibitors alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab) (//dc). |
| priorityDate | 2018-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.